BMedSci, DM, MRCP Raashid A. Luqmani (Consultant Rheumatologist/Senior Lecturer), MA, MRCP, MRCPath, MD Andrew R. Exley (Honorary Clinical Lecturer in Immunology/Senior Registrar), PhD, MRCP George D. Kitas (Consultant Rheumatologist and Senior Lecturer in Rheumatology), FRCP Paul A. Bacon (Professor of Rheumatology)
{"title":"10 Disease assessment and management of the vasculitides","authors":"BMedSci, DM, MRCP Raashid A. Luqmani (Consultant Rheumatologist/Senior Lecturer), MA, MRCP, MRCPath, MD Andrew R. Exley (Honorary Clinical Lecturer in Immunology/Senior Registrar), PhD, MRCP George D. Kitas (Consultant Rheumatologist and Senior Lecturer in Rheumatology), FRCP Paul A. Bacon (Professor of Rheumatology)","doi":"10.1016/S0950-3579(97)80052-0","DOIUrl":null,"url":null,"abstract":"<div><p>The improvement in survival with chemotherapy has resulted in a change of the natural history of the systemic vasculitis syndromes. The vasculitides are now viewed as chronic disease rather than fatal conditions. Their course is frequently characterized by relapse as well as the scars of irreversible organ damage from disease and drug toxicity. Assessment tools are available which can serve as outcome measures in clinical trials as well as a guide to better management of individual patients. Improvements in therapy in future are dependent on a better understanding of the pathogenesis of these conditions and the ability to assess disease accurately.</p></div>","PeriodicalId":77032,"journal":{"name":"Bailliere's clinical rheumatology","volume":"11 2","pages":"Pages 423-446"},"PeriodicalIF":0.0000,"publicationDate":"1997-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0950-3579(97)80052-0","citationCount":"108","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bailliere's clinical rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0950357997800520","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 108
Abstract
The improvement in survival with chemotherapy has resulted in a change of the natural history of the systemic vasculitis syndromes. The vasculitides are now viewed as chronic disease rather than fatal conditions. Their course is frequently characterized by relapse as well as the scars of irreversible organ damage from disease and drug toxicity. Assessment tools are available which can serve as outcome measures in clinical trials as well as a guide to better management of individual patients. Improvements in therapy in future are dependent on a better understanding of the pathogenesis of these conditions and the ability to assess disease accurately.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
